- Original article
- Open Access
Effect of airway vibratory mucus disintegration on clinical morbidity and management of chronic obstructive pulmonary disease patients
Egyptian Journal of Bronchology volume 7, pages 43–49 (2013)
Chronic obstructive pulmonary disease (COPD) is the fifth cause of morbidity and mortality in the developed world and represents a substantial economic and social burden. Patients experience a progressive deterioration characterized by airflow limitation, limited and declining performance status with chronic respiratory failure, and severe systemic manifestations/complications.
Aim of study
The aim of the study was to evaluate the effect of airway vibratory mucus disintegration on clinical morbidity and management of COPD patients.
Patients and methods
This prospective study was conducted on 30 COPD patients admitted to the Chest Department, Main University Hospital in Alexandria during the period from January 2012 to November 2012. The patients were subdivided into two groups: group I included 15 patients with COPD subjected to conventional treatment and group II included 15 patients with COPD subjected to conventional treatment and mucus disintegration by mechanical vibration.
A general improvement in cough and dyspnea was observed in the two groups after treatment. Six-minute walking distance was improved after treatment in both groups, but the improvement was statistically significant only in group II after treatment. Partial pressure of oxygen in the blood (PaO2), partial pressure of CO2 in the blood (PaCO2), and bicarbonate (HCO3) and oxygen saturation (SaO2) showed significant differences before and after treatment among group II patients. The total duration of hospital stay was significantly lower in group II patients than in group I patients.
We can conclude that there were no adverse effects. Flutter is simple to use, inexpensive, and fully portable, and once the patient and family are instructed its use, it does not require the assistance of a caregiver. Egypt J Broncho 2013 7:43–49
Viegi G, Pistelli F, Sherrill DL, Maio S, Baldacci S and Carrozzi L. Definition, epidemiology and natural history of COPD. Eur Respir J 2007; 30:993–1013.
Rabe KF, Hurd S, Anzueto A. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176:532–555.
Kimathianoki M, Mitrouska L and Georgopoulas D. Management of end –stage COPD. Eur Respir Mon 2006; 38:430–450.
Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: Systematic review and meta-analysis. Eur Respir J 2006; 28:523–532.
Boutin Forzano S, Morean D, Kaloboka S, Gay E, Bonnefoy X, Garrozzi L, et al. Reported prevalence and co-morbidity of asthma, chronic bronchitis and emphysema: A pan-European estimation. Int J Tuberc Lung Dis 2007; 11:695–702.
AM, Perez-Padilla R, Jardim JR. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): A prevalence study. Lancet 2005; 366:1875–1881.
Lindberg A, Eriksson B, Larsson LG, Eva R, Sandstrom T and Lundback B. Seven-year cumulative incidence of COPD in an age-stratified general population sample. Chest 2006; 129:879–885.
Johannessen A, Omenaas E, Bakke P, Gulsvik A. Incidence of GOLD-defined chronic obstructive pulmonary disease in a general adult population. Int J Tuberc Lung Dis 2005; 9:926–932.
Zielins J, Bednarek M, Gorecka D, Viegi G, Hurd S, CKW, et al. Increasing COPD awareness. Eur Respir J 2006; 27:833–852.
Bates DV. Chronic bronchitis and emphysema. In: Macklem PT, Permutt S, (editors). The lung in the transition between health and disease. New York: Marcel Dekker Inc; 1979. 12:1–13.
Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977; 1:1645–1648.
Konstan MW, Stern RC, Doershuk CF. Efficacy of the FLUTTER® device for airway mucus clearance in patients with cystic fibrosis. J Pediatr 1994; 124:689–693.
Izadi F, Hajbaghery M. Effects of pursed lips breathing on ventilation and activities of daily living in patient with COPD. Webmed Cent Rehab 2011; 2:1904–1915.
Kim DS, Kim YS, Chang JH. Prevalence of COPD in Korea: A population based spirometry survey. Am J Respir Crit Care Med 2005; 1729:842–847.
Stang P. The prevalence of COPD: Using smoking rates to estimate disease frequency in the general population. Chest 2000; 117:2–15.
Tazanakis N, Anagnostopoulou U, Filaditaki V. Prevalence of COPD in Greece. Chest 2004; 125:892–900.
Gunen H, Haceivliyagil S, Yetkin O. Prevelence of COPD: First epidemiological study of a large region in turkey. Eur J Intern Med 2008; 19:499–504.
Inversen L, Hannaford PC, Price DB. Is living in a rural area good for your respiratory health? Chest 2005; 128:2059–2067.
Sundblad BM, Larsson K, Nathell L. High rate of smoking abstinence in COPD patients smoking cessation by hospitalization. Nicotine Tob Res 2008; 10:883–890.
Hansen J. Arterial blood gases. Clin Chest Med 1999; 10:227–237.
Calverley P. Long acting bronchodilators in COPD: How many drugs do we need? ER J 2005; 26:190–191.
Lotters F, Vantol B, Kwakkel G. Effect of controlled inspiratory muscle training in patients with COPD: A meta analysis. Eur Respir J 2002; 20:570–577.
Backerman M, Magadel R, Weiner M. The effects of specific inspiratory muscle training in patient with COPD. Chest 2005; 128:3177–3182.
Hem Y, Cicek H, Akbayrak Y. The effects of breathing exercises on pulmonary function tests and arterial blood gas for the patients with the COPD. Gulhane Med J 2004; 46:1–9.
Jones PW, Harding G, Wiklund L. Tests of the responsiveness of the COPD assessment test following acute exacerbation and pulmonary rehabilitation. Chest 2012; 142:134–140.
About this article
Cite this article
Gad, A.Y., El-Shafe, S.A. Effect of airway vibratory mucus disintegration on clinical morbidity and management of chronic obstructive pulmonary disease patients. Egypt J Bronchol 7, 43–49 (2013). https://doi.org/10.4103/1687-8426.123985
- mucous vibration
- airflow limitation
- smoking cessation